Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) EPS (Basic): 2014-2025

Historic EPS (Basic) for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to -$22.96.

  • Viridian Therapeutics, Inc.\DE's EPS (Basic) rose 61.08% to -$22.96 in Q3 2025 from the same period last year, while for Sep 2025 it was -$202.13, marking a year-over-year increase of 50.31%. This contributed to the annual value of -$204.82 for FY2024, which is 21.43% up from last year.
  • Viridian Therapeutics, Inc.\DE's EPS (Basic) amounted to -$22.96 in Q3 2025, which was up 65.73% from -$66.99 recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's 5-year EPS (Basic) high stood at -$0.71 for Q4 2021, and its period low was -$256.73 during Q4 2023.
  • Its 3-year average for EPS (Basic) is -$55.72, with a median of -$51.64 in 2024.
  • Per our database at Business Quant, Viridian Therapeutics, Inc.\DE's EPS (Basic) surged by 97.19% in 2021 and then crashed by 24,991.55% in 2022.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's EPS (Basic) (Quarterly) stood at -$0.71 in 2021, then tumbled by 24,991.55% to -$178.15 in 2022, then tumbled by 44.11% to -$256.73 in 2023, then skyrocketed by 78.87% to -$54.24 in 2024, then soared by 61.08% to -$22.96 in 2025.
  • Its EPS (Basic) stands at -$22.96 for Q3 2025, versus -$66.99 for Q2 2025 and -$57.94 for Q1 2025.